Free tool
Stocks above their 200-day average
We cover 158 companies trading above their own 200-day average. The median market value in the group is $28.30B. Across the group, the median move over the past trading day is 0.00%. 100% of the 158 with a 200-day average trade above it. Price change over the past year runs from −3.5% to +114.2% across the middle 80 percent of the group, with a median of +26.9%.
Other lists in this group
Table
158 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| ABTT34.SA | Abbott Laboratories | $199.23B | Large cap | −16.35% |
| ABT | Abbott Laboratories | $198.74B | Large cap | −11.83% |
| GILD | Gilead Sciences, Inc. | $184.47B | Large cap | +32.51% |
| GIS.DE | Gilead Sciences, Inc. | $184.35B | Large cap | +33.64% |
| PFIZ34.SA | Pfizer Inc. | $161.53B | Large cap | +11.58% |
| PFE | Pfizer Inc. | $161.30B | Large cap | +18.72% |
| PFE.DE | Pfizer Inc. | $161.11B | Large cap | +22.96% |
| DHER34.SA | Danaher Corporation | $151.72B | Large cap | +0.89% |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% |
| DHR | Danaher Corporation | $151.40B | Large cap | +5.61% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% |
| BMYB34.SA | Bristol-Myers Squibb Company | $138.65B | Large cap | +40.74% |
| VRTX | Vertex Pharmaceuticals Incorporated | $138.63B | Large cap | +40.66% |
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| BRM.DE | Bristol-Myers Squibb Company | $137.92B | Large cap | +50.84% |
| MDT | Medtronic plc | $117.78B | Large cap | +2.29% |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% |
| MCK | McKesson Corporation | $104.54B | Large cap | +31.57% |
| ELV | Elevance Health, Inc. | $87.30B | Large cap | +32.12% |
| E1LV34.SA | Elevance Health, Inc. | $86.53B | Large cap | +21.66% |
| REGN34.SA | Regeneron Pharmaceuticals, Inc. | $85.16B | Large cap | +33.80% |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.89B | Large cap | +39.36% |
| CI | The Cigna Group | $74.22B | Large cap | −4.84% |
| MRK.DE | Merck KGaA | $70.28B | Large cap | +32.17% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| M1RN34.SA | Moderna, Inc. | $63.51B | Large cap | +462.13% |
| A1RG34.SA | argenx SE | $63.16B | Large cap | +36.97% |
| COR | Cencora, Inc. | $62.55B | Large cap | +13.45% |
| MRNA | Moderna, Inc. | $59.75B | Large cap | +496.25% |
| CSL.AX | CSL Limited | $59.72B | Large cap | −16.37% |
| 0QF.DE | Moderna, Inc. | $59.07B | Large cap | +550.51% |
| TAK | Takeda Pharmaceutical Company Limited | $58.60B | Large cap | +22.68% |
| 4502.T | Takeda Pharmaceutical Company Limited | $58.08B | Large cap | +36.03% |
| TAKP34.SA | Takeda Pharmaceutical Company Limited | $57.22B | Large cap | +18.03% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.25B | Large cap | +76.91% |
| BAY.WA | Bayer Aktiengesellschaft | $55.90B | Large cap | +76.59% |
| C1AH34.SA | Cardinal Health, Inc. | $55.77B | Large cap | +52.41% |
| CAH | Cardinal Health, Inc. | $55.45B | Large cap | +61.05% |
| EWL.DE | Edwards Lifesciences Corporation | $52.39B | Large cap | +11.65% |
| EW | Edwards Lifesciences Corporation | $52.32B | Large cap | +12.21% |
| BOX.DE | Becton, Dickinson and Company | $51.84B | Large cap | +1.73% |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% |
| B1DX34.SA | Becton, Dickinson and Company | $51.78B | Large cap | −113.87% |
| SHL.DE | Siemens Healthineers AG | $51.23B | Large cap | −14.18% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| HUM | Humana Inc. | $46.96B | Large cap | +33.14% |
| H1UM34.SA | Humana Inc. | $46.72B | Large cap | +24.36% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| H6D0.DE | Haleon plc | $44.85B | Large cap | +5.39% |
| HLN | Haleon plc | $44.72B | Large cap | +6.13% |
| HLN.L | Haleon plc | $44.62B | Large cap | +2.68% |
| T1EV34.SA | Teva Pharmaceutical Industries Limited | $44.24B | Large cap | +94.70% |
| TEVA | Teva Pharmaceutical Industries Limited | $44.19B | Large cap | +110.08% |
| A | Agilent Technologies, Inc. | $43.80B | Large cap | +31.46% |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% |
| QTS.DE | IQVIA Holdings Inc. | $43.01B | Large cap | −4.04% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| V2EE34.SA | Veeva Systems Inc. | $41.01B | Large cap | −18.65% |
| WAT | Waters Corporation | $40.67B | Large cap | +40.57% |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.39B | Large cap | +57.62% |
| VEE.DE | Veeva Systems Inc. | $40.02B | Large cap | +13.43% |
| VEEV | Veeva Systems Inc. | $39.78B | Large cap | −16.58% |
| WATC34.SA | Waters Corporation | $36.35B | Large cap | +24.76% |
| RPRX | Royalty Pharma plc | $35.71B | Large cap | +74.00% |
| RMD | ResMed Inc. | $34.13B | Large cap | −15.77% |
| I1LM34.SA | Illumina, Inc. | $34.10B | Large cap | +113.13% |
| ILU.DE | Illumina, Inc. | $34.08B | Large cap | +129.80% |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% |
| D1EX34.SA | DexCom, Inc. | $33.75B | Large cap | +9.64% |
| DXCM | DexCom, Inc. | $33.65B | Large cap | +16.47% |
| DC4.DE | DexCom, Inc. | $33.35B | Large cap | +21.06% |
| GEHC | GE HealthCare Technologies Inc. | $33.35B | Large cap | −1.15% |
| BIIB | Biogen Inc. | $32.66B | Large cap | +62.12% |
| C1NC34.SA | Centene Corporation | $32.65B | Large cap | +116.61% |
| BIIB34.SA | Biogen Inc. | $32.56B | Large cap | +47.86% |
| IDP.DE | Biogen Inc. | $32.39B | Large cap | +65.32% |
| CNC | Centene Corporation | $32.34B | Large cap | +127.01% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.43B | Large cap | +1.64% |
| B1NT34.SA | BioNTech SE | $28.32B | Large cap | +2.68% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| 22UA.DE | BioNTech SE | $28.28B | Large cap | +14.09% |
| MTD | Mettler-Toledo International Inc. | $28.10B | Large cap | +8.81% |
| MTO.DE | Mettler-Toledo International Inc. | $27.92B | Large cap | +13.15% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% |
| 4503.T | Astellas Pharma Inc. | $26.88B | Large cap | +53.57% |
| ROIV | Roivant Sciences Ltd. | $26.55B | Large cap | +206.51% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| I1NC34.SA | Incyte Corporation | $25.83B | Large cap | +41.91% |
| WST | West Pharmaceutical Services, Inc. | $24.63B | Large cap | +42.61% |
| 4543.T | Terumo Corporation | $23.67B | Large cap | −2.68% |
| STE | STERIS plc | $23.09B | Large cap | −4.41% |
| GH | Guardant Health, Inc. | $22.94B | Large cap | +169.17% |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +50.70% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.68B | Large cap | +25.88% |
| VIA.DE | Viatris Inc. | $19.41B | Large cap | +67.32% |
| VTRS | Viatris Inc. | $19.35B | Large cap | +66.19% |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.34B | Large cap | −4.32% |
| Z1BH34.SA | Zimmer Biomet Holdings, Inc. | $18.07B | Large cap | −5.04% |
| MEDP | Medpace Holdings, Inc. | $17.28B | Large cap | +30.74% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% |
| JAZZ | Jazz Pharmaceuticals plc | $16.89B | Large cap | +100.35% |
| ASND | Ascendis Pharma A/S | $16.41B | Large cap | +29.66% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| NBIX | Neurocrine Biosciences, Inc. | $15.92B | Large cap | +13.36% |
| N1BI34.SA | Neurocrine Biosciences, Inc. | $15.65B | Large cap | +7.37% |
| SOLV | Solventum Corporation | $15.58B | Large cap | +25.57% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% |
| BBIO | BridgeBio Pharma, Inc. | $15.52B | Large cap | +60.05% |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $15.44B | Large cap | +11.27% |
| C1OO34.SA | The Cooper Companies, Inc. | $15.12B | Large cap | −0.89% |
| ESF0.DE | Eurofins Scientific SE | $14.67B | Large cap | +12.65% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| 7733.T | Olympus Corporation | $14.46B | Large cap | +27.06% |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +42.93% |
| BAX | Baxter International Inc. | $13.70B | Large cap | +8.90% |
| PME.AX | Pro Medicus Limited | $13.66B | Large cap | −39.15% |
| B1AX34.SA | Baxter International Inc. | $13.60B | Large cap | +3.61% |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% |
| ORNAV.HE | Orion Oyj | $13.11B | Large cap | +21.27% |
| ICLR | ICON Public Limited Company | $13.03B | Large cap | −2.91% |
| CORT | Corcept Therapeutics Incorporated | $12.95B | Large cap | +71.81% |
| PEN | Penumbra, Inc. | $12.72B | Large cap | +21.02% |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% |
| FME.DE | Fresenius Medical Care AG | $12.64B | Large cap | −2.61% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +4.97% |
| ELAN | Elanco Animal Health Incorporated | $12.53B | Large cap | +35.64% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.52B | Large cap | +308.99% |
| FMS | Fresenius Medical Care AG | $12.51B | Large cap | −3.21% |
| R1VT34.SA | Revvity, Inc. | $12.50B | Large cap | +22.81% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.45B | Large cap | +26.78% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% |
| TEM | Tempus AI, Inc. | $12.40B | Large cap | −6.49% |
| EHC | Encompass Health Corporation | $11.92B | Large cap | −1.75% |
| DVAI34.SA | DaVita Inc. | $11.70B | Large cap | +18.80% |
| T1CH34.SA | Bio-Techne Corporation | $11.51B | Large cap | +23.42% |
| DVA | DaVita Inc. | $11.41B | Large cap | +30.89% |
| TECH | Bio-Techne Corporation | $11.35B | Large cap | +29.33% |
| BTSG | BrightSpring Health Services, Inc. | $11.32B | Large cap | +156.37% |
| CYTK | Cytokinetics, Incorporated | $11.01B | Large cap | +109.36% |
| AXSM | Axsome Therapeutics, Inc. | $10.85B | Large cap | +69.99% |
| GKOS | Glaukos Corporation | $10.65B | Large cap | +89.83% |
| KRYS | Krystal Biotech, Inc. | $10.65B | Large cap | +143.67% |
| MOH | Molina Healthcare, Inc. | $10.57B | Large cap | +13.35% |
| PRAX | Praxis Precision Medicines, Inc. | $10.54B | Large cap | +704.28% |
| KYMR | Kymera Therapeutics, Inc. | $10.53B | Large cap | +197.09% |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% |
| HSIC | Henry Schein, Inc. | $10.30B | Large cap | +31.02% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.